Modality
mAb
MOA
HER2
Target
Nectin-4
Pathway
Neuroinflam
MDDPBC
Development Pipeline
Preclinical
~Jan 2013
→ ~Apr 2014
Phase 1
~Jul 2014
→ ~Oct 2015
Phase 2
~Jan 2016
→ ~Apr 2017
Phase 3
Jul 2017
→ Jul 2030
Phase 3Current
NCT08485080
1,375 pts·PBC
2019-11→TBD·Completed
NCT08511958
2,690 pts·PBC
2019-03→TBD·Terminated
NCT06659512
758 pts·PBC
2017-07→2030-07·Not yet recruiting
4,823 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-07-234.3y awayPh3 Readout· PBC
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P3
Not yet…
P3
Termina…
P3
Complet…
Catalysts
Ph3 Readout
2030-07-23 · 4.3y away
PBC
CompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08485080 | Phase 3 | PBC | Completed | 1375 | PFS |
| NCT08511958 | Phase 3 | PBC | Terminated | 2690 | ORR |
| NCT06659512 | Phase 3 | PBC | Not yet recr... | 758 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| ION-3857 | Ionis | Preclinical | Nectin-4 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 |